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1Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, ConnecticutABSTRACT The 37-residue peptide hormone islet amyloid polypeptide (IAPP) plays a central role in diabetes pathology.
Although its amyloid fiber aggregation kinetics and cytotoxicity to b-cells are well documented, few reports have directly
assessed the role of fibers in cell-based toxicity experiments. Here, we report that amyloid formation of IAPP can be strongly
inhibited by the extracellular environment of live cells. For example, fiber formation is more strongly suppressed in cell culture
medium than in aqueous buffer. The serum component of the medium is responsible for this inhibition. Although amyloid for-
mation was previously shown to be catalyzed by both synthetic and chloroform-extracted phospholipid surfaces, it is instead
inhibited by membrane surfaces prepared directly from the plasma membranes of an immortal b-cell line. This disparity is recon-
ciled by direct assessment of fibers in cell-culture-based toxicity experiments. We discovered that fibers are nontoxic if they
are washed free of adsorbed nonfibrillar components. Moreover, toxicity is not only rescued when monomers are added
back to fibers but is greater than what is observed from the precursor alone. Our results are interpreted in light of the capacity
of the fiber surface to template amyloid nucleation.INTRODUCTIONA critical characteristic of type II diabetes is the dysfunction
and subsequent death of insulin-secreting b-cells of the
pancreas. The 37-residue peptide hormone islet amyloid
polypeptide (IAPP) is thought to play a central role in dia-
betes pathology because more than 90% of diabetes patients
possess IAPP amyloid deposits (1,2), and rodents transgenic
for human IAPP (hIAPP) exhibit spontaneous b-cell
dysfunction and development of diabetes-like symptoms,
including elements of early progression such as insulinitis
(3). Challenges in the treatment of type I diabetes through
islet cell transplantation have also been attributed to the
amyloidogenic properties of this hormone (4).
IAPP possesses a broad range of conformations and activ-
ities that are strongly dependent on its environment. IAPP is
a natively unstructured peptide that readily forms amyloid
fibers rich in b-sheet. IAPP also readily binds anionic phos-
pholipid bilayers, with model lipid membranes typically re-
ported as strong accelerants of fiber assembly. This may be
relevant to disease, as a rise in anionic lipid (e.g., phospha-
tidic acid) content has been associated with metabolic
changes in diabetes (5,6). Other relevant factors may include
insulin (7), vesicle curvature (8), pH (9,10), ionic strength
(11), and nonanionic lipids (8). Upon binding, IAPP adopts
a predominantly a-helical structure that spans the first ~22
residues of the sequence (12–14). Helicity is observed in sta-
bilized IAPP structures that permit leakage of synthetic ves-
icles via pore formation (15,16). Fiber-induced membrane
disruption by IAPP has also been reported (17).Submitted May 8, 2014, and accepted for publication September 22, 2014.
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0006-3495/14/12/2559/8 $2.00IAPP is toxic to b-cells (18,19), crosses the cellular
bilayer, and localizes to mitochondria (18,20). Independent
studies have reported that intermediate, oligomeric struc-
tures are responsible for toxicity (19,21). In a previous
study, we established an indirect connection between mem-
brane-bound structures and toxicity to b-cells by observing
toxicity from IAPP mutants that form membrane-associated
helical structure, but do not form amyloid (18). It is im-
portant to note that we and others (18,22) have shown that
mutants that disable the propensity for b-sheet formation
also have a diminished capacity for toxicity. A reduction
of IAPP-induced toxicity has also been observed in the pres-
ence of small molecules that target and bind helical struc-
tures (23).
The most common approach for correlating membrane
activity to toxicity of IAPP is to use synthetic lipid vesicles.
This creates a conflict because biophysical investigation
drives the selection of lipid components that enhance time-
scales or signal/noise ratios to facilitate mechanistic in-
terpretation. Sensitivity to cellular conditions is typically
addressed by measuring trends as a function of changes in
lipid content, such as surface charge or inclusion of choles-
terol. In our own work, we have shown that IAPP binding
to synthetic membranes ceases below 50% anionic lipid
content (24). Others have similarly reported a loss of mem-
brane-inducible structure at an anionic lipid content of less
than 50% (22). Cell membranes contain much less than 50%
anionic content, and yet in previous studies we quantita-
tively reported surface adsorption by IAPP in cell culture
on the 120 min timescale (18). Those studies were conduct-
ed with live cells under conditions in which cellular uptake
mechanisms were suppressed. We reported that under toxichttp://dx.doi.org/10.1016/j.bpj.2014.09.047
2560 Schlamadinger and Mirankercellular conditions, such adsorption is followed by cell-
penetrating peptide (CPP)-like translocation of the plasma
and/or lysosomal membrane, localization to the mitochon-
drial compartment, followed by mitochondrial dysfunction
and subsequent cell death (18).
Engel et al. (17) reported observables wholly at odds with
such a model. Specifically, they concluded that fibril growth
at the surface of a vesicle leads directly to membrane disrup-
tion, and suggested this as a physical basis for downstream
toxicity. These disparate findings highlight the need to not
only find a more representative model lipid membrane but
to also directly investigate the relationship between mem-
brane activity, fibers, and toxicity of IAPP.MATERIALS AND METHODS
Materials
Chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless
otherwise specified. Synthetic IAPP was purchased from Genscript (Piscat-
away, NJ) and the W.M. Keck facility (New Haven, CT). The protein
included the naturally occurring C-terminal amidation and an oxidized
disulfide bond between residues 2 and 7 at >98% purity. Protein stocks
were generated as described previously (18) but for the use of 50% aceto-
nitrile/0.2% formic acid as eluent from a MacroSpin column (The Nest
Group, Southborough, MA). This stock was split into aliquots, lyophilized,
and stored at 80C. Aliquots were dissolved with water to 1 mM or
200 mM and used immediately in cell-based or kinetics experiments.
The lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dio-
leoyl-sn-glycero-3-phospho-(10-rac-glycerol) (DOPG, sodium salt) were
purchased from Avanti Polar Lipids (Alabaster, AL), and vesicles were
extruded with 100 nm filters (23). Alexa-488 carboxylic acid, succinimidyl
ester was purchased from Life Technologies (Carlsbad, CA).
IAPP fibers (IAPPfib) were generated by incubating 50 mM hIAPP in
50 mM sodium phosphate buffer, 100 mM KCl, pH 7.4, for ~15 h. Fibers
were pelleted at 21,000 g for 30 min and resuspended three times using
water. After the final spin, the pellet was resuspended to create a 1 mM
(monomeric units and assuming no loss) stock of fibers. This stock, as
well as a diluted 100 mM stock in water, was made fresh on the same
day for each cell-viability or kinetic assay.
Alexa-488-labeled IAPP was prepared as described previously (18).
Briefly, IAPP was incubated with Alexa-488 carboxylic acid, succinimidyl
ester on a MacroSpin column for 4 h. Labeled IAPP was eluted from the
MacroSpin column with 50% acetonitrile/0.2% formic acid solution. This
was then diluted with 7 M guanidinium hydrochloride solution to a total
organic content of<5%. Labeled protein was then purified by reverse-phase
high-performance liquid chromatography, and identity was confirmed by
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry.
Aliquots were lyophilized and stored at 80C. Stocks at 120 mM in water
were prepared and used immediately before imaging experiments.Kinetic assays
For experiments measuring the effects of cell culture media, reactions were
initiated by dilution of protein stock solution into 50 mM sodium phosphate
buffer (100 mM KCl, pH 7.4) containing 100–200 nM thioflavin T (ThT;
Acros Organics, Geel, Belgium). For experiments measuring the effects
of giant plasma membrane vesicles (GPMVs), reactions were initiated in
10 mM HEPES buffer (150 mM NaCl, 2 mM CaCl2, pH 7.4) containing
250 nM ThT. Formation of amyloid was monitored by fluorescence (exci-
tation 450 nm, emission 485 nm) in nonbinding black 96-well plates
(Greiner BioOne, Monrose, NC) using a FluoDia T70 fluorescence plateBiophysical Journal 107(11) 2559–2566reader (Photon Technology International, Birmingham, NJ). Each kinetic
trace was fit to a sigmoidal form:
I ¼ ðb2 þ m2tÞ þ ðb1 þ m1tÞe
t50t
t
1þ et50tt
where I is the fluorescence intensity, t is time, and b, m, and t are dependent
fitting variables. The parameter t50 represents the time at which fiber forma-tion is midway between the upper and lower baselines extended, and corre-
sponds to an inflection point if the upper and lower baselines are parallel.
All samples were run in triplicate and error bars represent standard
deviations.Cell culture
Rat insulinoma INS-1 cells (832/13; Dr. Gary W. Cline, Department of In-
ternal Medicine, Yale University) were cultured at 37C and 5% CO2 in
phenol-red-free RPMI 1640 medium supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin (Life Technologies), and 2% INS-1
stock solution (500 mM HEPES, 100 mM L-glutamine, 100 mM sodium
pyruvate, and 2.5 mM b-mercaptoethanol). Cells were passaged when
they reached ~95% confluence (0.25% Trypsin-EDTA; Life Technologies).
COS-1 cells (from immortalized African green monkey kidney; CRL-
1650 ATCC) were cultured at 37C and 5% CO2 in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and 1% peni-
cillin/streptomycin (all from Life Technologies). Cells were passaged when
they reached ~95% confluence (0.25% Trypsin-EDTA; Life Technologies).GPMV isolation
GPMVs were isolated from INS-1 and COS-1 cells according to established
methods (25). Briefly, cells were plated in 35 mm dishes and cultured for
48 h. Cells were washed with a 10 mM HEPES, 150 mM NaCl, 2 mM
CaCl2 (pH ¼ 7.4) twice and were then exposed to 10 mM N-ethyl malei-
mide (NEM; Sigma Aldrich) for 1 h (COS-1 cells) or 2 h (INS-1 cells).
Cells exposed to 10 mM HEPES, 150 mM NaCl, 2 mM CaCl2 (pH ¼
7.4) for the same time period (NEM samples) served as a background con-
trol. Both NEM and NEMþ samples were removed via pipet from dishes
after the incubation period and further concentrated to matched volumes us-
ing spin concentrators (3 kDa and 100 kDa molecular mass cutoff; Milli-
pore, Billerica, MA). Aliquots of NEM and NEMþ samples were taken
after zero, one, and two 5- to 10-min spins at 2880 g (3 kDa cutoff) or
720 g (100 kDa cutoff) and used in kinetic reactions. Total phosphate
was measured in the most concentrated NEM and NEMþ samples and
in synthetic lipid vesicle stocks as previously described (16). The phosphate
content in NEM samples was below the detection limit of the assay.GPMV imaging
Images were acquired in wide-field mode on an in-house-built inverted mi-
croscope as described previously (26). Fluorescent imaging was achieved
with wide-field illumination at 488 nm. The camera gain and exposure
time settings were matched between images. Samples for imaging were pre-
pared by mixing 60 mL of NEMþ or NEM material and 2.5 mM Alexa-
488 IAPP (in pure water) into 10 mM HEPES, 150 mM NaCl, 2 mM
CaCl2 (pH ¼ 7.4) buffer (total volume ¼ 300 mL). Samples were incubated
30 min before imaging.Cell viability
Cell viability was measured colorimetrically using the Cell-Titer Blue
(CTB; Promega, Madison, WI) fluorescence-based assay. Cells were plated
at a density of 5000 cells/well in 96-well plates (BD Biosciences, San
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FIGURE 1 Cell culture medium inhibits hIAPP fiber formation. Fiber
formation is initiated by dilution of hIAPP stock in water to 40 mM in re-
actions containing 50 mM phosphate buffer and 100 mM KCl (pH ¼ 7.4)
diluted to the indicated percentage of medium (RPMI, phenol-red free).
(a) Representative normalized kinetic traces (monitored using 100 nM
ThT fluorescence) are presented. (b) Statistics of reaction midpoints, t50,
from repeat analyses of a. Open bars are t50 values (45 mM hIAPP) obtained
Role of Amyloid Fibers in Cytotoxicity 2561Diego, CA). Peptide was directly introduced to each well 24 h after
passaging and plating, and then further incubated for an additional 72 h.
After the incubation period, 20 mL CTB reagent was added to each well
and incubated at 37C and 5% CO2 for 2.5–3.5 h. The fluorescence of
the resorufin product was measured on a FluoDia T70 fluorescence plate
reader (Photon Technology International, Birmingham, NJ). All wells
included the same amount of water to account for different concentrations
of peptide added to sample wells. Wells that included water vehicle, but not
peptide, served as the negative control (0% toxic), and wells containing
10% DMSO served as the positive control (100% toxic). Percent toxicity
was calculated using the following equation:
%Toxicity ¼ 100

100 ,
hSi  hPi
hNi  hPi

Each independent variable is the average fluorescence of eight plate repli-
cates from the negative control (hNi), positive control (hPi), and samples
(hSi). Results presented for viability experiments are an average of three
independent experiments (i.e., 24 replicates total). Error bars represent
the standard error of the mean of the three independently conducted
experiments.
for reactions at the indicated percentage of culture medium divided by the
t50 of buffer-only reactions. Dark gray bars are the relative t50 obtained for
reactions containing RPMI medium without the fetal bovine serum compo-
nent. Light gray bars are the relative t50 values of a reaction in buffer con-
taining 0.6 mM purified bovine or human serum albumin. This corresponds
to a concentration approximately equivalent to that present in 2%RPMI cell
culture medium.RESULTS
Little is known about how environments that are obligatory
for measurement influence the membrane activity and amy-
loidogenic nature of IAPP. Here, we designed experiments
to address how the extracellular environment of live cells in-
fluences de novo and seeded amyloid assembly. We utilized
a model membrane vesicle system derived directly from a
pancreatic b-cell line and assessed the influence of the mem-
brane on amyloid kinetics. The toxicity of soluble IAPP,
preformed fibers, and soluble IAPP in the presence of pre-
formed fibers was compared quantitatively.
Environments that are important for cell-based experi-
ments strongly inhibit IAPP fiber formation. We initiated
fiber kinetics by diluting a 1 mM protein stock solution in
water into buffer. At a final protein concentration of
40 mM in 50 mM phosphate buffer and 100 mM KCl
(pH ¼ 7.4), the midpoint, t50, of such an assembly reaction
is 10,300 5 500 s. In marked contrast, the same reaction
performed in 96% RPMI medium resulted in no detection
of amyloid assembly. Inhibition by RPMI medium is dose
dependent, with as little as 0.4% medium (99.6% phosphate
buffer) yielding inhibition of t50 > 2-fold (Fig. 1). At 2%
RPMI medium, the t50 is beyond our timescale of moni-
toring (>14 hr). Omission of the fetal bovine serum compo-
nent of RPMI medium results in a rate of IAPP conversion
to fiber similar to that observed in buffer alone (Fig. 1 b),
indicating that the protein fraction is responsible for inhibi-
tion. Purified albumin (bovine and human, 0.6 mM)
extended relative t50 values to 2.6 5 0.1 and 2.5 5 0.1,
respectively, compared with a reaction conducted in the
absence of albumin. The concentration of bovine serum al-
bumin (BSA) present in 1% RPMI is 0.6 mM (Fig. S1 in the
Supporting Material), suggesting that other components of
the serum fraction are relevant to the inhibitory properties
of the medium. Since b-cells surround capillaries andsecrete into the circulatory system, IAPP is released into
an environment in which an amyloid inhibitor (albumin) is
already present at high concentrations (27).
Plasma-membrane-derived vesicles isolated from
cultured mammalian cells inhibit fiber formation. We pre-
pared GPMVs from INS-1 cells according to established
methods, using NEM as the vesiculating reagent (25).
NEM was chosen as the reagent to generate GPMVs
because it is a comparatively mild, irreversible blocker of
free sulfhydryls that are present predominantly, if not exclu-
sively, on proteins. Alternative protocols use a relatively
strong, nonspecific cross-linking mixture, 25 mM parafor-
maldehyde/2 mM dithiothreitol (PFA/DTT). Moreover,
working with both the blocker and cross-linking systems re-
vealed that trace components of the PFA/DTT mixture could
affect IAPP reaction t50 values (not shown). However, NEM
has no effect on the t50 of IAPP (Fig. S2). Our reference
reaction (NEM cell free) is a 40 mM IAPP fiber formation
reaction in 10 mM HEPES, 150 mM NaCl, 2 mM CaCl2
(pH ¼ 7.4), and 10 mM NEM (Fig. 2) and has a t50 of
18,900 5 400 s. In the absence of vesiculant, the reaction
has a t50 of 18,100 5 200 s, indicating that the vesiculant
has no independent effect on the conversion rate. The
HEPES buffer is the standard buffer system used for
GPMV isolation, and therefore the absolute t50 values re-
ported for GPMVexperiments differ slightly from those re-
ported in the phosphate buffer system (see above). Given the
inhibitory nature of the cell culture medium described
above, cells were washed extensively before incubation
with vesiculant. Moreover, the t50 was compared withBiophysical Journal 107(11) 2559–2566
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FIGURE 2 Cell-derived plasma membrane vesicles inhibit fiber forma-
tion. GPMVs were used as a reagent added to standardized 40 mM IAPP fi-
ber formation reactions. (a) Schematic depicting the stepwise concentration
of GPMVs using a 100 kDa molecular mass cutoff centrifugal concentrator
for both NEMþ and NEM samples. GPMVs are depicted as blue open cir-
cles, and residual medium components are depicted as red dots. (b) Repre-
sentative kinetic traces are shown for the GPMVs added directly to the fiber
formation reaction (zero spin, NEMþ), and for washes that have been
concentrated ~3 (one spin, NEMþ) and ~15 (two spins, NEMþ). For
comparison, vesicle-free conditions were created using washes that did
not contain the vesiculating reagent (two spins, NEM). A representative
trace is shown in which 11 mM 50:50 DOPC/DOPG synthetic lipid vesicles
(in monomer units) were prepared in the same buffer. (c) Statistics of reac-
tion midpoints, t50, from fits to repeated analyses of b. Open bars are data
from INS-1 GPMVs. Solid bars indicate data from analyses using COS-1
GPMVs. A further control is shown from NEM-containing samples that
were never in contact with cells (NEM cell free). In panels b and c, green
corresponds to the two-spin NEM sample, pink corresponds to the zero-
spin NEMþ sample, orange corresponds to the one-spin NEMþ sample,
and purple corresponds to the two-spin NEMþ sample. To see this figure
in color, go online.
2562 Schlamadinger and Mirankersolutions derived by procedures that were identical in every
respect except for the omission of NEM (indicated as
NEM samples). Inhibition by materials gathered by this
procedure can be attributed to the GPMVs using a dose-
response assay. We concentrated the GPMV isolate
(NEMþ samples) stepwise using a 100 kDa molecular
mass cutoff centrifugal concentrator to pass many soluble
proteins originating from the medium while concentrating
the GPMVs (Fig. 2 a). A representative example (Fig. 2 b)
clearly shows that concentration of the GPMVs yields a
dose dependence. We also observed a similar dose-depen-
dent extension of t50 using a 3 kDa molecular mass cutoff
centrifugal concentrator (Fig. S3). Repeats at 100 kDa
show relative t50 values delayed by factors of 2.2 5 0.6,
2.5 5 0.1, and 4.2 5 0.3, respectively (Fig. 2 c). Since
NEM samples do not modulate the t50 of IAPP reactionsBiophysical Journal 107(11) 2559–2566compared with our reference reaction, residual media com-
ponents from the GPMV isolation procedure are unlikely
contributors to the inhibition observed by NEMþ samples
(GPMV-containing samples).
Inhibition by GPMVs is not cell-line specific. Insulin and
rodent IAPP, both of which are secreted by INS-1 cells,
inhibit IAPP fiber formation (7,28). To determine whether
GPMV inhibition is cell-line specific, we repeated the
assays using GPMVs isolated from COS-1 cells, a kidney
cell line derived from African green monkey (Fig. 2 b).
Relative t50 values extended to 1.8 5 0.2, 3.4 5 0.4, and
>5 in NEMþ samples, further indicating that the GPMV-
induced t50 extension is not a result of inhibition by residual
rodent IAPP or insulin secreted by INS-1 cells. Higher rela-
tive t50 values in the presence of COS-1 GPMVs compared
with INS-1 GPMVs is likely a result of a slightly higher con-
centration of GPMVs isolated from COS-1 cells (see
below). The progression of average relative t50 values in
the presence of INS-1 NEM samples remained largely un-
changed, with values of 1.0 5 0.1, 1.1 5 0.1, and 1.1 5
0.1. The average relative t50 values obtained for COS-1
NEM samples were 1.1 5 0.1, 1.1 5 0.1, and 1.1 5
0.1. GPMV isolates plainly extended the t50 of IAPP regard-
less of cell type.
GPMV inhibition of fiber formation kinetics is in direct
contrast to the catalysis observed by synthetic lipid vesicles.
Kinetics in the presence of 50:50 DOPC/DOPG lipid vesi-
cles at similar total phosphate concentrations show a strong
enhancement of fiber kinetics of 40 mM IAPP (Fig. 2 a). Re-
actions containing DOPC/DOPG lipid vesicles with 11 mM
total phosphate reduce the t50 5-fold compared with the t50
measured in a reference sample. In this work, total phos-
phate serves as an indirect measure of lipid concentration
in GPMVs. The phosphate content for each INS-1 GPMV
NEMþ sample was 2, 7, and 35 mM, respectively. The phos-
phate content for each COS-1 GPMV NEMþ sample was 4,
12, and 60 mM, respectively. Plainly, we observe a reduction
of the t50 of IAPP in the presence of synthetic liposomes,
and an extension of t50 in the presence of cell-derived lipo-
somes at total phospholipid concentrations that are semi-
quantitatively matched.
To further support the role of GPMVs in these assays, we
directly determined that IAPP binds both INS-1 and COS-1
GPMVs (Fig. 3). We imaged GPMVs with laser and white-
light illumination using wide-field fluorescence microscopy.
Alexa-488-labeled IAPP was observed to localize uniformly
to the surface of INS-1 GPMVs and occasional contami-
nating dead cells (Fig. 3, top). For this work, we regard
dead cells as an equivalent reagent to GPMVs. Labeled
IAPP also localizes to the surface of COS-1 GPMVs
(Fig. 3, bottom). NEM control samples showed no
GPMVs and had high background from the labeled IAPP
under matched detector settings (not shown), consistent
with IAPP partitioning to GPMVs in NEMþ samples. The
Alexa-488 images of NEMþ material depict a relatively
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FIGURE 4 The toxicity of fresh IAPP is increased by addition of
nontoxic fibers. IAPP toxicity to INS-1 cells was measured colorimetrically
72 h after exposure to the indicated total (fiber þ monomer) concentration
of IAPP. Cells were exposed to IAPPfresh (open bars) or 1 mM of preformed
IAPPfib mixed with IAPPfresh (gray bars). Horizontal lines are drawn at the
toxicity levels measured for 10 mM IAPPfresh (56%5 6%, dotted) or 10 mM
IAPPfib (5%5 2%, dashed).
FIGURE 3 IAPP binds GPMVs. Samples were prepared as described in
Fig. 2 except for the addition of 2.5 mM-labeled IAPP. Representative
white-light (right) and fluorescence (left) image pairs are shown for
GPMVs derived from INS-1 cells (top) and COS-1 cells (bottom), respec-
tively. Scale bar is 10 mm.
Role of Amyloid Fibers in Cytotoxicity 2563uniform distribution of IAPP on the membrane surface,
which is consistent with observations on the surface of
GUVs made from chloroform/methanol-extracted lipids
(29). We previously reported that IAPP forms fluorescent
puncta on live cells (18). This suggests that puncta for-
mation that is large enough to be resolved by wide-field
microscopy may be a live-cell-specific result. Overall, our
observations clearly indicate that IAPP binds our plasma-
membrane-derived GPMVs.
Freshly prepared IAPP dissolved in pure water (IAPPfresh)
is toxic to INS-1 cells. As a function of peptide concentra-
tion, toxicity is sigmoidal (Fig. S4 a). IAPPfresh reduced
cell viability by 1.0% 5 0.7% (2 mM), 4.2% 5 0.4%
(3 mM), 7% 5 1% (5 mM), and 56% 5 6% (10 mM) after
72 h incubation (Fig. 4), which are comparable to previously
published toxicities of IAPP to INS-1 cells (18). Experi-
ments conducted with a different synthetic batch of IAPP
and different style well plates showed a slightly lower
toxicity (~13 mM elicited 50% toxicity; Fig. S4 a). Indeed,
we routinely assessed the dose response of all lots of syn-
thetic and expressed IAPP, as variation in the EC50 on the
order of 2- to 3-fold is common between lots.
IAPP fibers (IAPPfib) are not toxic to cells. Application of
10 mM IAPPfib directly to the cell culture medium showed lit-
tle toxicity compared with the same concentration of freshly
dissolved peptide (Fig. 4). Importantly, since our preformed
amyloid fibers were grown in phosphate buffer, washed, and
then concentrated in water, the resulting treated fibers
reduced cell viability by only 5% 5 2%. Treated fibers
used in cell-viability assays retained the capacity to affect
amyloid kinetics reactions. Seeded kinetics wholly bypassed
the lag phase of the de novo kinetics profile but still retaineda profilewith a lag phase (Fig. S5). Moreover, the slope of the
profile at the t50 was far greater than that calculated for as-
sembly governed only by primary nucleation. Both of these
characteristics are consistent with secondary (fiber-depen-
dent) nucleation as observed previously for IAPP (30,31).
Fiber-based toxicity can be rescued. When treated fibers
were added simultaneously with freshly dissolved protein
(IAPPfresh þ IAPPfib), cell viability was greatly reduced
compared with the same amount of freshly dissolved protein
alone (Fig. 4). Cell viability was reduced by 8%5 2% (1mM
IAPPfreshþ 1 mM IAPPfib), 16%5 6% (2 mM IAPPfreshþ 1
mM IAPPfib), and 59% 5 7% (4 mM IAPPfresh þ 1 mM
IAPPfib). Note that the concentration of IAPPfib in experi-
ments that included IAPPfresh þ IAPPfib is 10 times less
than the amount used to measure toxicity of IAPPfib directly
as described above. A strong reduction in cell viability was
also observed when the experiment was conducted with a
different lot of IAPP and well-plate format (Fig. S4 b).
Toxicity in the presence of fibers is unlikely to be the
result of elongation (Fig. 5). As with the de novo kinetics,
the cell culture medium halted the seeded fiber kinetics of
IAPP. In the presence of 2 mM IAPPfib, as little as 4% me-
dium (96% buffer) extended the t50 of a seeded reaction
nearly 3-fold compared with the reaction initiated in phos-
phate buffer alone. This inhibition was potent, albeit not
as potent as de novo inhibition, in which as little as 0.4%
medium was sufficient to suppress amyloid formation by a
comparable amount (Fig. 1). A critical difference is that
the cell-based experiments were conducted in 100% me-
dium, a 10-fold lower concentration of IAPPfresh, and a 2-
fold lower concentration of IAPPfib. We previously reported
that b-cell uptake of IAPP in culture medium is completeBiophysical Journal 107(11) 2559–2566
a b
FIGURE 5 The medium inhibits fiber formation seeded with preformed
fibers. (a) Representative normalized kinetic traces for 40 mM IAPPfresh,
2 mM IAPPfib, and the indicated percentage of RPMI medium. The dotted
line demarcates the time taken for 10 mM IAPPfresh (a toxic concentration)
to partition from the medium to cultured cells (18). (b) Statistics of reaction
midpoints, t50, from fits to repeat analyses of (a).
2564 Schlamadinger and Mirankerwithin 2 h (Fig. 5 a, vertical dotted line) (18). It is likely,
therefore, that soluble peptide is taken up by cells long
before extracellular conversion to amyloid occurs.DISCUSSION
It is particularly challenging to associate molecular structure
with gains of toxic function in amyloid systems with disor-
dered peptide precursors. Multiple conformers and oligo-
meric states are populated and interconvert, resulting in
several gains of function that act together to contribute to
cell death. In this study, we investigated the impact of the
extracellular environment on the amyloid fiber assembly
of IAPP and the role of preamyloid states in assembly and
toxicity. Our observations provide a very new perspective.
Specifically, 1) the medium used to culture cells strongly
suppresses amyloid formation; 2), giant vesicles generated
from the plasma membrane of cultured cells suppress amy-
loid formation; 3), IAPP fibers are nontoxic provided they
are washed free of precursor; and 4), combinations of fiber
and monomer act synergistically to elicit greater toxicity
than would either component alone. Our findings clearly
point to a critical role for fibers in gains of toxic function.
However, it is not the fibers per se that are toxic; rather, it
is their capacity to catalyze the formation of toxic species
from precursor material that is relevant.
Primary toxicity can be defined as deriving from toxic
species that form independently of preexisting fibers. The
cellular environment, including media and vesicles prepared
from plasma membrane, strongly delays amyloid kinetics,
and fibers possess no intrinsic toxicity. This suggests that,
at least in cell culture, extracellular fiber formation is not
a requirement for toxicity. Our results do not exclude the
possibility that once IAPP is inside cells, amyloid formation
occurs, resulting in toxicity. However, toxicity is also
observable from a rodent sequence variant of IAPP with
no evidence of fiber formation. Not only is rodent IAPPBiophysical Journal 107(11) 2559–2566capable of toxicity, but it follows a time course and subcel-
lular localization profile comparable to that observed for the
readily amyloidogenic human protein (18).
Secondary toxicity, conceptually similar to secondary
nucleation, can be defined as formation of toxic species
that is dependent on the presence of preformed fibers. The
notion that the presence of fibers is required for toxicity is
strongly supported by studies showing that membrane-cata-
lyzed amyloid formation by IAPP coincides with a loss of
membrane integrity (17). Moreover, it has been observed
that protein preincubated into the lag phase of its amyloid
conversion enhances the formation of toxic species (32).
The latter studies permit the inference that either nonfibrillar
toxic oligomers are created in the lag period or, alterna-
tively, primary nucleation dominates over secondary nucle-
ation in the lag phase, generating low populations of fiber.
Here, we directly assessed secondary toxicity by first
showing that preparations of amyloid were nontoxic. We
then rescued toxicity by mixing subtoxic quantities of solu-
ble and fibrous IAPP into the cell culture (Fig. 5). This
behavior strongly suggests that although the fibers them-
selves are nontoxic, they can behave as catalysts for the for-
mation of toxic species.
The origin of apparent secondary toxicity remains un-
clear. One possibility is that secondary toxicity is directly
related to nonbreakage forms of secondary nucleation, or
the capacity of an amyloid fiber to act as a catalytic surface
for the formation of new fibers from precursor material
(30,31). IAPP and other systems possess kinetic profiles
that require such secondary processes. In Ab from Alz-
heimer’s disease, Cohen et al. (30) observed secondary
toxicity in human neuroblastoma cells. They found that
Ab toxicity was predominantly elicited from monomeric
peptide (4 mM) in the presence of fibers (40 nM) rather
than by monomeric peptide alone. As oligomers were
observed during the kinetics analysis, the fiber-dependent
toxicity in the presence of freshly dissolved peptide was
attributed to the catalyzed generation of directly observed
toxic oligomeric species. IAPP and Ab are similar in length,
physicochemical properties, and sequence (33). These sim-
ilarities have been recognized and resulted in diverse obser-
vations, such as suppression of Ab self-assembly by IAPP
mimics (34) and cocrystal structures of Ab and IAPP bound
to insulin-degrading enzyme (35). Therefore, we conjecture
that oligomeric species that rapidly populate in the presence
of preformed Ab fibers (30) may also be generated by mix-
tures of IAPPfresh and IAPPfib. Unlike the case with Ab, how-
ever, nonamyloid, toxic oligomer preparations of IAPP have
yet to be purified. For both Ab and IAPP, secondary toxicity
is stronger than primary toxicity. Collectively, these findings
implicate secondary toxicity as the dominant component of
amyloid precursor-induced cellular dysfunction.
The inhibition of fiber formation by GPMVs was wholly
unexpected. Several labs, including our own, have reported
and characterized the catalysis of IAPP amyloid formation
Role of Amyloid Fibers in Cytotoxicity 2565by anionic phospholipid bilayers (8,24,36). However, the
lipid and cholesterol content, net lipid charge, and size of
the lipid vesicle all affect fiber kinetics differently. Larger
vesicles that do not contain any anionic lipid vesicles or
include cholesterol extend fiber kinetics, whereas smaller
lipid vesicles that contain anionic lipids accelerate IAPP
fiber kinetics (8). Studies in this area have led to models
of binding, pore formation, translocation, and catalysis
(16,18,37), and, importantly, identified protein structures
rich in a-helix. Here, we recapitulated these observables
by showing the catalytic behavior of synthetic anionic lipid
vesicles at total phosphate concentrations comparable to
what was assessed using GPMVs. Previous studies have
shown that unilamellar vesicles generated from lipids iso-
lated by chloroform extraction from INS-1 cells (29), whole
pancreas from a diabetic human, or whole chicken liver (24)
catalyzed IAPP amyloid formation. Plainly, some other fac-
tor within the plasma membrane is relevant to inhibition.
This may include a component that is excluded by solvent
extraction, such as protein, an as-yet-unidentified lipid com-
ponent, or a physical property such as curvature. Here, we
observed IAPP binding to cell-derived membrane, whereas
others have seen IAPP binding to membrane from chloro-
form-derived GUVs (29). However, two-component, syn-
thetic large unilamellar vesicles matched to the typical net
charge of cell membranes did not show any binding (24).
Therefore, we assert that both lipids and proteins affect
catalysis, but conjecture that surface-expressed protein com-
ponents play an underappreciated role in plasma membrane
binding.CONCLUSIONS
We observe that preformed fibers are not a toxic species, but
rather elicit toxicity when combined with freshly dissolved
IAPP. This secondary toxicity is quantitatively stronger than
the toxicity observed with freshly dissolved IAPP (primary
toxicity) alone, and may be an important feature of diabetic
pathology. We conjecture that this toxicity is derived from
the amyloid fiber surface-based catalysis that is evident
in IAPP and Ab systems. We base our conclusions on a sur-
prising observation, namely, that both the extracellular envi-
ronment and plasma membrane of cells strongly suppress
amyloid conversion. This finding is in direct contrast to
many observations that membranes composed of synthetic
lipid catalyze the formation of fibers. We propose that the
lipid vesicles described in this work can be used to study
binding, disorder-to-order structural transitions, membrane
disruption, translocation, and pore-formation gains of func-
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